Pfizer’s RSV Vaccine: Two Positive Votes Don’t Necessarily Add Up To AdComm Endorsement
Executive Summary
Pfizer got positive standalone votes on safety and efficacy for its RSV vaccine in older adults at a US FDA advisory committee, but only three advisors – a minority of the 12-member panel – endorsed both the safety and effectiveness of the firm’s candidate.
You may also be interested in...
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
A Milestone Meeting For US FDA: Vaccine Reviews After COVID
The tandem reviews by a US FDA advisory committee of two RSV vaccine candidates from Pfizer and GSK is a milestone event for the agency. They are the first non-COVID vaccine BLAs to go to committee since the pandemic began – and the debut of the new vaccine office leadership at FDA.
After ACIP Gambit, Pfizer, GSK Take RSV Vaccines To US FDA Adcomm
The Vaccines and Related Biological Products Advisory Committee is scheduled to consider the RSV vaccine candidates on 28 February and 1 March.